Filspari denied as non-formulary by Aetna?

Aetna's specific coverage criteria for filspari are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Classifies Filspari as Non-Formulary — and Your Path to Coverage

Filspari (sparsentan) is a newer FDA-approved agent for IgA nephropathy, and many Aetna formularies have not yet placed it on a covered tier. A non-formulary denial does not mean the drug is excluded from coverage forever — it means you must pursue a formulary exception, which is the standard process for gaining coverage of a medically necessary drug not currently listed on the plan's drug list.

Formulary exception requests succeed most often when the prescriber clearly documents that no formulary alternative is clinically appropriate for this specific patient.

## Your Federal Appeal Rights

• Formulary exception request: Most Aetna plans offer a formulary exception pathway before or alongside formal appeal. Submit a formulary exception request with supporting clinical documentation as a first step.
• Internal appeal (ACA §2719 / ERISA §503): If the exception is denied, you have the right to a full-and-fair internal appeal. File within the deadline on your denial notice.
• External review: After internal appeal denial, an independent reviewer can assess whether the non-formulary denial is consistent with generally accepted medical practice. The window is typically approximately four months from the original denial.
• Expedited review: Available if your condition is urgent or rapidly progressing.

## Documentation to Gather

1. Diagnosis confirmation — biopsy-confirmed IgA nephropathy, current clinical status, proteinuria and kidney function trends as documented in chart. 2. Formulary alternative review — your prescriber should document each formulary alternative Aetna would suggest, explain why each is not clinically equivalent or appropriate for this patient, and state that no adequate formulary substitute exists. 3. Prescriber medical-necessity letter — explaining the clinical rationale for Filspari specifically, referencing the FDA-approved prescribing label and the relevant nephrology guideline organization generically. 4. Prior treatment history — any agents already tried, with dates and outcomes, to show the clinical journey that leads to Filspari.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception criteria (available in your plan documents or on the provider portal). Build a response grid:

| Exception Criterion | Your Evidence | |---|---| | No clinically appropriate formulary alternative | [Prescriber letter — each alternative reviewed and rejected with reason] | | Diagnosis confirmed and on-label use | [Biopsy report + FDA label] | | Clinical necessity documented | [Chart notes + prescriber letter] | | Specialist involvement | [Nephrologist name + NPI] |

Attach the FDA prescribing information for Filspari. A strong formulary exception letter from the nephrologist that goes through each potential alternative one by one is the most persuasive document in a non-formulary appeal.